Epithelial Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmA ®b808 in Combination With Pembrolizumab in Advanced Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma; Non-small Cell Lung Cancer, Squamous or Non-squamous; Urothelial Carcinoma; Renal Cell Carcinoma, Clear Cell; Castration-resistant Prostate Cancer; Ovarian Cancer, Epithelial; TNBC - Triple-Negative Breast Cancer; Colorectal Cancer Interventions: Biological: XmAb®808; Biological: Keytruda® (pembrolizumab) Sponsor: Xencor, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2022 Category: Research Source Type: clinical trials

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb ®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma; Non-small Cell Lung Cancer, Squamous or Non-squamous; Urothelial Carcinoma; Renal Cell Carcinoma, Clear Cell; Castration-resistant Prostate Cancer; Ovarian Cancer, Epithelial; TNBC - Triple-Negative Breast Cancer; Colorectal Cancer Interventions: Biological: XmAb®808; Biological: Keytruda® (pembrolizumab) Sponsor: Xencor, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2022 Category: Research Source Type: clinical trials

Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma
Condition: Ovarian Carcinoma Intervention: Sponsor: Sohag University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2022 Category: Research Source Type: clinical trials